Global Novel Oral Anticoagulants Drugs Market is expected to grow at a CAGR of XX% during the forecast period. The market is driven by factors such as increasing incidence of cardiovascular diseases, growing geriatric population, and rising prevalence of chronic kidney disease. However, high cost associated with novel oral anticoagulants drugs may hamper the growth of this market. The global novel oral anticoagulants drugs market has been segmented on the basis of type into direct thrombin inhibitors and factor Xa inhibitors; on the basis of application into hospital and drug stores; and on the basis of region into North America, Latin America, Europe, Asia Pacific and Middle East & Africa. North America accounted for a major share in terms of revenue in 2017 owing to high adoption rate among patients suffering from cardiovascular diseases in this region. Europe is expected to witness significant growth during the forecast period owing to increasing awareness about novel oral anticoagulants drugs among physicians as well as patients suffering from cardiovascular diseases.
- Novel oral anticoagulants drugs are a new class of anticoagulant that is not associated with the risk of bleeding complications.
- Novel oral anticoagulants drugs are used to prevent blood clots from forming in the body and to treat deep vein thrombosis, pulmonary embolism, and other conditions that can cause serious problems if a clot breaks loose and travels through the bloodstream.
- Novel oral anticoagulants drugs have been shown to be more effective than warfarin in preventing strokes in people who have atrial fibrillation or other heart rhythm disorders that increase their risk for stroke.
- Novel oral anticoagulants drugs are also used to prevent blood clots from forming during surgery or following childbirth.
- The novel oral anticoagulant market is expected to grow due to an increasing number of patients suffering from cardiovascular diseases.
Industry Growth Insights published a new data on “Novel Oral Anticoagulants Drugs Market”. The research report is titled “Novel Oral Anticoagulants Drugs Market research by Types (Direct Thrombin Inhibitor, Factor Xa Inhibitors), By Applications (Hospital, Drugs Stores, Other), By Players/Companies Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Boehringer Ingelheim, Daiichi Sankyo”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Novel Oral Anticoagulants Drugs Market Research Report
By Type
Direct Thrombin Inhibitor, Factor Xa Inhibitors
By Application
Hospital, Drugs Stores, Other
By Companies
Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Boehringer Ingelheim, Daiichi Sankyo
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Novel Oral Anticoagulants Drugs Market Report Segments:
The global Novel Oral Anticoagulants Drugs market is segmented on the basis of:
Types
Direct Thrombin Inhibitor, Factor Xa Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Stores, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol-Myers Squibb
- Bayer
- Pfizer
- Johnson & Johnson
- Boehringer Ingelheim
- Daiichi Sankyo
Highlights of The Novel Oral Anticoagulants Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Direct Thrombin Inhibitor
- Factor Xa Inhibitors
- By Application:
- Hospital
- Drugs Stores
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Novel Oral Anticoagulants Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Novel oral anticoagulants drugs are medications that have not been used before in the treatment of blood clotting disorders. They work by preventing blood from clotting, which can reduce the risk of stroke or heart attack.
Some of the major companies in the novel oral anticoagulants drugs market are Bristol-Myers Squibb, Bayer, Pfizer, Johnson & Johnson, Boehringer Ingelheim, Daiichi Sankyo.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Novel Oral Anticoagulants Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Novel Oral Anticoagulants Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Novel Oral Anticoagulants Drugs Market - Supply Chain
4.5. Global Novel Oral Anticoagulants Drugs Market Forecast
4.5.1. Novel Oral Anticoagulants Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Novel Oral Anticoagulants Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Novel Oral Anticoagulants Drugs Market Absolute $ Opportunity
5. Global Novel Oral Anticoagulants Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Type
5.3.1. Direct Thrombin Inhibitor
5.3.2. Factor Xa Inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Novel Oral Anticoagulants Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Drugs Stores
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Novel Oral Anticoagulants Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Novel Oral Anticoagulants Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Novel Oral Anticoagulants Drugs Demand Share Forecast, 2019-2026
9. North America Novel Oral Anticoagulants Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Drugs Stores
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Type
9.7.1. Direct Thrombin Inhibitor
9.7.2. Factor Xa Inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Novel Oral Anticoagulants Drugs Demand Share Forecast, 2019-2026
10. Latin America Novel Oral Anticoagulants Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Drugs Stores
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Type
10.7.1. Direct Thrombin Inhibitor
10.7.2. Factor Xa Inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Novel Oral Anticoagulants Drugs Demand Share Forecast, 2019-2026
11. Europe Novel Oral Anticoagulants Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Drugs Stores
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Type
11.7.1. Direct Thrombin Inhibitor
11.7.2. Factor Xa Inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Novel Oral Anticoagulants Drugs Demand Share, 2019-2026
12. Asia Pacific Novel Oral Anticoagulants Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Drugs Stores
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Type
12.7.1. Direct Thrombin Inhibitor
12.7.2. Factor Xa Inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Novel Oral Anticoagulants Drugs Demand Share, 2019-2026
13. Middle East & Africa Novel Oral Anticoagulants Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Drugs Stores
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Novel Oral Anticoagulants Drugs Market Size and Volume Forecast by Type
13.7.1. Direct Thrombin Inhibitor
13.7.2. Factor Xa Inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Novel Oral Anticoagulants Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Novel Oral Anticoagulants Drugs Market: Market Share Analysis
14.2. Novel Oral Anticoagulants Drugs Distributors and Customers
14.3. Novel Oral Anticoagulants Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bristol-Myers Squibb
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bayer
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson & Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Boehringer Ingelheim
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Daiichi Sankyo
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook